key: cord-0989546-jxltrieg authors: Conti, Andrea; Damiani, Giovanni; Ruggeri, Roberta; Odorici, Giulia; Farnetani, Francesca; Pigatto, Paolo Daniele Maria; Pellacani, Giovanni title: Switching infliximab in psoriatic patients during COVID‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies date: 2021-08-16 journal: Dermatol Ther DOI: 10.1111/dth.15088 sha: 2974887e9fd367d902e7e975898d56dfd595112c doc_id: 989546 cord_uid: jxltrieg During this pandemic, dermatological infusion centers were partially unavailable, suspended or even reconverted to guest COVID‐19 patients, consequently infliximab (IFX) infusions became challenging for their both logistic arrangement and also for patients' COVID‐19 phobia. This 48 weeks follow‐up retrospective observational study included 37 PsO patients that underwent IFX SB2 during pandemic in two primary dermatological referral centers. In 23 (62.1%) we had to switch from IFX to other biologics, not motivated by adverse reactions, contraindication or even loss of response but only to pandemic related conditions. Nine patients underwent interclass switching and 15 underwent intraclass switching; interestingly 2 patients that underwent adalimumab SB‐5 switched back to IFX. Interclass switching was privileged in elder patients and smokers. All patients at week 48 achieved PASI 100. Intra‐ and interclass switchings are both safe and effective strategies in psoriatic patients with COVID‐19 phobia and/or difficulties to undergo infliximab infusions. Although COVID-19 pandemic continues to challenge healthcare systems worldwide, medical decisions should be directed by the evidence-based medicine principles 1,2 ; at the same time, contradicting data on psoriasis (PsO) and biologics are present in literature and social media 3-5 ending up to influence patients' compliance. 6 Infliximab (IFX), a humanized IgG1 monoclonal antibody targeting tumor necrosis factor (TNF)-α, was the first biologic drug authorized for PsO. Among biologics, only infliximab and its biosimilars, such as SB-2, has a pro-kilo parenteral administration that forces patients every 8 weeks to undergo a '60 min infusion and a total of 3 h hospitalization for each infusion. 7 This laborious protocol, that maintains patients hospitalized longer than other biologics, virtually, also exposes them to a higher possibility of SARS-CoV-2 infection. During this pandemic, dermatological infusion centers were partially unavailable, suspended or even reconverted to guest COVID-19 patients, consequently IFX infusions became challenging for their both logistic arrangement and also for patients with COVID-19 phobia. Andrea Conti and Giovanni Damiani contributed equally to this study. Thus, several IFX responders asked to switch to another anti-psoriatic biologic drug and, at the moment, no indications are present to orient intraclass or interclass switchings. 8 During the entire study, patients were clinically assessed by two board certified dermatologists (A. C., G. D) that performed Psoriasis Area Severity Index (PASI), 11 Psoriasis Epidemiology Screening Tool (PEST), 12 ClASsification criteria for Psoriatic Arthritis (CASPAR). 13 Patients were evaluated at T0 (Baseline), T1 (4 weeks), T2 (16 weeks), T3 (32 weeks), T4 (40 weeks), and T5 (48 weeks) during in-person and teledermatological visits. Patients treated with IFX SB-2 were evaluated in person during the infusions at T0, T1, T2, T3, T4 and T5, while patients switched to subcutaneous biologics were evaluated in person only at T0, T2, and T4 and in teledermatology at T1, T3, and T5 IFX remains an effective biologic drug for both PsO and PsA patients, but its infusions were difficult to deliver during COVID-19 pandemic due to both patient-related (i.e., COVID-19 phobia or Cabin fever syndrome) and hospital-related (i.e., infusions room unavailability) causes. 14 Furthermore, during pandemic chronic patients undergoing immunosuppressive drugs globally decreased their compliance 6 due to media disinformation and fake news, 15 discordant position on therapies, COVID-19, and related outcomes. 3, 4, 16, 17 In line with National Psoriasis Foundation recommendations, 18 The Italian Society of Dermatology (SIDeMaST) suggested not to discontinue biologics in absence of COVID-19, 19 while in case of COVID-19, symptomatic or asymptomatic, positions remain still discordant. In fact, anti-TNF alpha (i.e., IFX) seems to increase SARS-CoV-2 infection rate, 4 20 the decreased drug immunogenicity 26 and the higher REFERENCES 1. GBD 2017 Italy Collaborators. Italy's health performance, 1990-2017: findings from the global burden of disease study 2017 Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration COVID-19 vaccination and psoriatic patients under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers COVID-19 knowledge prevents biologics discontinuation: data from an Italian multicenter survey during RED-ZONE declaration Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy Increased airway inflammation in patients with psoriasis Severe psoriasis-oral therapy with a new retinoid Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire The ClASsification for psoriatic ARthritis (CASPAR) criteria-a retrospective feasibility, sensitivity, and specificity study COVID-19 and psoriasis: recommendation for patients on regular infliximab therapy CoVerifi: a COVID-19 news verification system Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by Interleukin-17 inhibitors Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 1 Board Members of the SIDeMaST. The Italian dermatologic community facing COVID-19 pandemic: recommendation from the Italian society of dermatology and venereology Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series SARS-CoV-2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell Type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study Saliva as a future field in psoriasis research Predicting secukinumab fast-responder profile in psoriatic patients: advanced application of artificial-neural-networks (ANNs) Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) T cell epitope mapping of secukinumab and ixekizumab in healthy donors From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intraversus interclass switching strategies